New drug combo for advanced stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three drugs (Disitamab Vedotin, Tunlametinib, and a PD-1 antibody) for advanced stomach cancer that has HER2 protein. It is for patients who have tried at least two prior treatments or cannot tolerate standard therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced stomach cancer and have already tried at least two prior treatments (or cannot tolerate them).
- Your tumor has a high level of HER2 protein (2+ or 3+ on a lab test).
- You have at least one measurable tumor that can be seen on scans.
- You are 18 years or older.
- You have adequate organ function (kidney, liver, blood counts).
- You have not taken Disitamab Vedotin as your first or second treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (disitamab vedotin and sintilimab) plus radiation for people with HER2-positive advanced stomach cancer that has worsened after two prior treatments. The goal is to see if this approach can shrink tumors and help patients live longer.
This trial tests a new combination of drugs (RC48, sintilimab, and SOX chemotherapy) for people with stomach or gastroesophageal junction cancer that cannot be removed by surgery, has not been treated before, and has a specific HER2 score (1+ or 2+). The goal is to shrink the tumor enough to possibly allow surgical removal.
This study tests a new combination of targeted therapy (DP303c) with either a drug called simmitinib or a liposomal form of irinotecan for people with advanced stomach or GEJ cancer. The goal is to see if these combinations can shrink tumors or slow cancer growth.
This trial tests two drugs, disitamab vedotin and trastuzumab, for people with HER2-positive stomach or gastroesophageal junction cancer that has spread or come back after at least one prior treatment. The goal is to see if this combination can help shrink tumors.
This trial tests whether adding immunotherapy (sintilimab) to chemotherapy with or without lenvatinib helps people with HER2-negative stomach cancer that has spread. It compares three different treatment combinations to find the best option.
This trial tests a combination of two immunotherapy drugs (iparomlimab/tuvonralimab) plus chemotherapy (XELOX) in people with advanced stomach or gastroesophageal junction cancer that is HER2-negative and has low PD-L1 levels. It aims to see if this treatment can help shrink tumors or slow the disease.
Hear when a new Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.